BCMA-CS1 HLE BiTE (Amgen)

N/A

Report date: 2026/03/19 16:59:38

Base Information

Drug NameBCMA-CS1 HLE BiTE (Amgen)

Drug Alias Nameanti-CD3/anti-BCMA/anti-CS-1 trispecific T-cell engager (Amgen)anti-CD3/anti-BCMA/anti-SLAMF7 trispecific T-cell engager (Amgen)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTumor necrosis factor ligand superfamily member 13 modulatorsSLAM family member 7 modulators

TargetsSLAM family member 7T cell surface glycoprotein CD3Tumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A